Anti-HLA antibodies in regenerative medicine stem cell therapy

Charron, Dominique; Suberbielle-Boissel, Caroline; Tamouza, Ryad; Al-Daccak, Reem

doi:10.1016/j.humimm.2012.06.010

Cited by 13 publications

(14 citation statements)

References 85 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This represents a potential problem, as the innate and the cellular immune response to stem cells are not fully understood. In addition, the humoral immune response following injection of allogeneic stem cells needs to be taken into account [62]. The presence of anti-HLA antibodies after hESc and hiPSC therapy and preformed antibodies prior to injection might compromise and limit the survival and the efficacy of the bioengineered organ.…”

Section: Resultsmentioning

confidence: 99%

Immune responses to bioengineered organs

Ochando

Charron

Baptista

et al. 2017

Current Opinion in Organ Transplantation

Self Cite

View full text Add to dashboard Cite

Purpose of reviewOrgan donation in the United States registered 9079 deceased organ donors in 2015. This high percentage of donations allowed organ transplantation in 29 851 recipients. Despite increasing numbers of transplants performed in comparison with previous years, the numbers of patients that are in need for a transplant increase every year at a higher rate. This reveals that the discrepancy between the demand and availability of organs remains fundamental problem in organ transplantation.Recent findingsDevelopment of bioengineered organs represents a promising approach to increase the pool of organs for transplantation. The technology involves obtaining complex three-dimensional scaffolds that support cellular activity and functional remodeling though tissue recellularization protocols using progenitor cells. This innovative approach integrates cross-thematic approaches from specific areas of transplant immunology, tissue engineering and stem cell biology, to potentially manufacture an unlimited source of donor organs for transplantation.SummaryAlthough bioengineered organs are thought to escape immune recognition, the potential immune reactivity toward each of its components has not been studied in detail. Here, we summarize the host immune response toward different progenitor cells and discuss the potential implications of using nonself biological scaffolds to develop bioengineered organs.

show abstract

Section: Resultsmentioning

confidence: 99%

Immune responses to bioengineered organs

Ochando

Charron

Baptista

et al. 2017

Current Opinion in Organ Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since the problem arose with myoblast transplantation, many research groups focused their attention on stem cells but the risk for immunorejection was underestimated. In fact ESCs once differentiated in the host tissues' ability to lose their “immune-privilege state” thanks to MHC class I expression, favoured by host microenvironment [126]. Similarly IPSCs can be recognized by CD4+ and CD8+ T-cells through unnatural-manipulated genes and also autologous stem cells can be modified by long-term culture or supports materials [111, 124, 125].…”

Section: Discussionmentioning

confidence: 99%

“…In particular autologous stem cells can provoke inflammation and rejection maybe as a consequence of genetic manipulation or long-term culture (required for their correction and expansion) or their combination with matrix structures. Similarly, ESCs express low levels of HLA class I but only before differentiation; once injected and after reaching the host organ, the MHC disparities lead to acute antibody-mediated rejection (AMR) [126]. Furthermore if IgG antibodies directed against HLA class I antigen of donor cells are already present at the time of transplantation hyperacute rejection (HAR) will occur [127, 128].…”

Section: Cell Therapy and Immune Responsesmentioning

confidence: 99%

“…Interestingly evidences arose that HLA/MHC molecules could have a role in signalling transduction so that the prediction of efficacy of transplantation is further reduced. MHC expression in transplanted cells could be influenced by the host microenvironment (e.g., INF- γ or hypoxia exposure) [126]. Anti-HLA antibodies mediated injury through both complement-dependent and independent pathways and through the binding with HLA donor cells; this binding could result in activation, proliferation, and cytokines production, leading to amplification of damage [129].…”

Section: Cell Therapy and Immune Responsesmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies

Farini

Sitzia

Erratico³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Muscular dystrophies (MDs) are a heterogeneous group of diseases, caused by mutations in different components of sarcolemma, extracellular matrix, or enzymes. Inflammation and innate or adaptive immune response activation are prominent features of MDs. Various therapies under development are directed toward rescuing the dystrophic muscle damage using gene transfer or cell therapy. Here we discussed current knowledge about involvement of immune system responses to experimental therapies in MDs.

show abstract

“…A study of rabbit fractures has shown that allogenic MSCs performed just as well as autologous MSCs in repairing bone, with no increase in immunogenicity [54]. Although the view of the future clinical utility of these cells is not uniformly optimistic [55], the successful outcomes of these trials have the potential to significantly change the field of orthopedic surgery.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Biologic adjuvants and bone: current use in orthopedic surgery

Smith

Goldstein

Ekstein

2015

Curr Rev Musculoskelet Med

View full text Add to dashboard Cite

Normal bone healing is a complex process that eventually restores original structure and function to the site of trauma. However, clinical circumstances such as nonunion, critical-sized defects, systemic bone disease, and fusion procedures have stimulated a search for ways to enhance this normal healing process. Biologics are an important part of this search and many, including bone marrow aspirate concentrate, demineralized bone matrix, platelet-rich plasma, bone morphogenic proteins, and platelet-derived growth factor, are currently in clinical use. Many others, including mesenchymal stem cells, parathyroid hormone, and Nel-like molecule-1 (NELL-1) will likely be in use in the future depending on the results of preclinical and clinical trials.

show abstract

Anti-HLA antibodies in regenerative medicine stem cell therapy

Cited by 13 publications

References 85 publications

Immune responses to bioengineered organs

Immune responses to bioengineered organs

Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies

Biologic adjuvants and bone: current use in orthopedic surgery

Contact Info

Product

Resources

About